| Cat. No. |
Size |
Price |
Figures |
|---|
RP11786-1 mg
| 1 mg | $ 47.50 | MSDS: 20080715205608 (PDF)
References:
- Potter P, et al. Differential processing and presentation of the H-2D(b)-restricted epitope from two different strains of influenza virus nucleoprotein. J. Gen. Virol. May 2001; 82(Pt 5): 1069-1074.
- Reid AH, et al. Novel origin of the 1918 pandemic influenza virus nucleoprotein gene. J. Virol. Nov 2004; 78(22): 12462-12470.
- Mullin AE, et al. Increased amounts of the influenza virus nucleoprotein do not promote higher levels of viral genome replication. J. Gen. Virol. Dec 2004; 85(Pt 12): 3689-3698.
|
|---|
| Full Name | |
| Alias |
Influenza Virus Nucleoprotein (44-52) |
Sequence
(one-letter code) |
CTELKLSDY |
Sequence
(three-letter code) | {CYS}{THR}{GLU}{LEU}{LYS}{LEU}{SER}{ASP}{TYR} |
|---|
| Description | CEF25 is an HLA-A*01 restricted epitope from influenza virus nucleoprotein (44-52). CEF25 is a CEF control peptide. GenScript also provides CEF25 by net weight based on peptide content. All CEF peptides are used in the stimulation of IFNγ release from CD8+ T cells in indifiduals with defined HLA types. |
|---|
| Formula | C46H74N10O17S |
|---|
| M.W. | 1071.21 |
|---|
| Purity | > 95% |
|---|
| Storage | Store the peptide at -20°C. Keep container tightly closed. |
